Observational Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 7, 2015; 21(37): 10688-10696
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10688
Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity
Liliana Belgioia, Stefano Vagge, Dario Agnese, Stefania Garelli, Roberto Murialdo, Giuseppe Fornarini, Silvana Chiara, Fabio Gallo, Almalina Bacigalupo, Renzo Corvò
Liliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy
Stefania Garelli, Department of Medical Physics, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy
Roberto Murialdo, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy
Giuseppe Fornarini, Silvana Chiara, Department of Medical Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy
Fabio Gallo, Section of Biostatistics, Department of Health Sciences, University of Genoa, 16132 Genoa, Italy
Author contributions: Belgioia L, Agnese D and Bacigalupo A performed the literature search and wrote the manuscript; Vagge S, Garelli S, Murialdo R, Fornarini G, Chiara S and Corvò R participated in drafting the paper and performing critical revision for important intellectual content; Vagge S and Gallo F performed the statistical analysis.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no actual or potential conflicts of interest to declare.
Data sharing statement: No additional data is available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Liliana Belgioia, MD, University Research, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy. liliana.belgioia@unige.it
Telephone: +39-328-4833384 Fax: +39-010-5556393
Received: March 2, 2015
Peer-review started: March 4, 2015
First decision: April 24, 2015
Revised: May 12, 2015
Accepted: July 18, 2015
Article in press: July 18, 2015
Published online: October 7, 2015
Core Tip

Core tip: This study evaluated intensity-modulated radiotherapy with simultaneous integrated boost in anal canal cancer of prevalent Human papilloma virus (HPV)-positive patients. The results show excellent outcomes in HPV-positive tumors, and suggest that an intensified radiotherapy schedule associated with chemotherapy is safe and allows the obtaining of oncologic results comparable to the standard schedule without an increase in acute toxicity.